The Supreme Court ruled today that mifepristone will remain accessible during the appeals process of the April 7 Texas ruling that would have declared the Food and Drug Administration (FDA) approval of the drug invalid.  BIO interim President and CEO, Rachel King, made the following statement:  “Today’s decision is an important development for patients and for ensuring access to approved medicines. However, we must redouble our efforts to preserve and protect the FDA’s long-standing role as the authority in determining the safety and efficacy of medicines. As legal and medical experts have noted, the courts do not have the expertise or medical training to make these types of complex scientific determinations. At BIO, we will continue to organize and mobilize on behalf of patients and will work tirelessly to ensure that regulatory decision-making is grounded in scientific and medical expertise.”